Metabolites (Apr 2024)

Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells

  • Cristina Trejo-Solís,
  • Rosa Angélica Castillo-Rodríguez,
  • Norma Serrano-García,
  • Daniela Silva-Adaya,
  • Salvador Vargas-Cruz,
  • Elda Georgina Chávez-Cortéz,
  • Juan Carlos Gallardo-Pérez,
  • Sergio Zavala-Vega,
  • Arturo Cruz-Salgado,
  • Roxana Magaña-Maldonado

DOI
https://doi.org/10.3390/metabo14050249
Journal volume & issue
Vol. 14, no. 5
p. 249

Abstract

Read online

The metabolic reprogramming that promotes tumorigenesis in glioblastoma is induced by dynamic alterations in the hypoxic tumor microenvironment, as well as in transcriptional and signaling networks, which result in changes in global genetic expression. The signaling pathways PI3K/AKT/mTOR and RAS/RAF/MEK/ERK stimulate cell metabolism, either directly or indirectly, by modulating the transcriptional factors p53, HIF1, and c-Myc. The overexpression of HIF1 and c-Myc, master regulators of cellular metabolism, is a key contributor to the synthesis of bioenergetic molecules that mediate glioma cell transformation, proliferation, survival, migration, and invasion by modifying the transcription levels of key gene groups involved in metabolism. Meanwhile, the tumor-suppressing protein p53, which negatively regulates HIF1 and c-Myc, is often lost in glioblastoma. Alterations in this triad of transcriptional factors induce a metabolic shift in glioma cells that allows them to adapt and survive changes such as mutations, hypoxia, acidosis, the presence of reactive oxygen species, and nutrient deprivation, by modulating the activity and expression of signaling molecules, enzymes, metabolites, transporters, and regulators involved in glycolysis and glutamine metabolism, the pentose phosphate cycle, the tricarboxylic acid cycle, and oxidative phosphorylation, as well as the synthesis and degradation of fatty acids and nucleic acids. This review summarizes our current knowledge on the role of HIF1, c-Myc, and p53 in the genic regulatory network for metabolism in glioma cells, as well as potential therapeutic inhibitors of these factors.

Keywords